Sugi Predict

Sugi Predict / Compounds / SCHEMBL129133

SCHEMBL129133

SCHEMBL129133

O=C(CBr)c1ccc(F)c(C(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 4/20 0.56
▸ GSK3B P49841 4/20 0.56
▸ TAS1R3 Q7RTX0 2/20 0.46
▸ TAS1R1 Q7RTX1 2/20 0.46
▸ TAS1R2 Q8TE23 2/20 0.46
▸ VNN1 O95497 6/20 0.44
▸ KCNQ3 O43525 1/20 0.44
▸ KCNQ2 O43526 1/20 0.44
▸ KCNE1 P15382 1/20 0.44
▸ KCNQ1 P51787 1/20 0.44
▸ PTPN7 P35236 1/20 0.43
▸ DUSP3 P51452 1/20 0.43
▸ HDAC8 Q9BY41 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30129534 1.00 PTPN1 (0.56) PTPN1GSK3BTAS1R3TAS1R1TAS1R2
SCHEMBL474257 0.86 GSK3B (0.56) PTPN1GSK3BKCNQ3KCNQ2KCNE1
SCHEMBL5365512 0.86 GSK3B (0.59) PTPN1GSK3B
SCHEMBL5430185 0.84 TAS1R3 (0.47) TAS1R3TAS1R1TAS1R2VNN1KCNQ3
SCHEMBL7779146 0.84 PTPN1 (0.58) PTPN1GSK3B
SCHEMBL30580694 0.84 PTPN1 (0.58) PTPN1GSK3B
SCHEMBL5312305 0.83 TAS1R3 (0.49) GSK3BTAS1R3TAS1R1TAS1R2VNN1
SCHEMBL2074095 0.83 TAS1R3 (0.49) TAS1R3TAS1R1TAS1R2VNN1KCNQ3
SCHEMBL2063413 0.83 TAS1R3 (0.46) TAS1R3TAS1R1TAS1R2VNN1KCNQ3
SCHEMBL20703063 0.82 VNN1 (0.44) TAS1R3TAS1R1TAS1R2VNN1KCNQ3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258323-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2025-03-25 — — US disclosed
CN-118164965-A Pyrimidine-triazole-fluorine substituted phenyl cyclopropylamine derivative and application thereof 郑州大学 2024-06-11 — — CN disclosed
US-20240182452-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-06-06 — — US disclosed
CN-111212647-B Dihydro oxadiazinones 拜耳股份有限公司 2024-05-14 — — CN disclosed
CN-117924169-A Dihydroquinoline derivative and pharmaceutical application thereof in resisting influenza 山东大学齐鲁医院 2024-04-26 — — CN disclosed
US-11897867-B2 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer BAYER AKTIENGESELLSCHAFT (DE) 2024-02-13 — — US disclosed
US-11773070-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2023-10-03 — — US disclosed
US-11773070-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2023-10-03 — — US disclosed
US-11773070-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2023-10-03 — — US disclosed
US-20230292759-A1 PHENYL COMPOUND AND PLANT DISEASE CONTROL METHOD SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-09-21 — — US disclosed
WO-2009130232-A1 PYRAZOLO [1, 5 -A] PYRAZINE DERIVATIVES AS ANTAGONISTS OF V1B RECEPTORS GLAXO GROUP LIMITED (GB) 2009-10-29 — — WO disclosed
WO-2009130232-A1 PYRAZOLO [1, 5 -A] PYRAZINE DERIVATIVES AS ANTAGONISTS OF V1B RECEPTORS GLAXO GROUP LIMITED (GB) 2009-10-29 — — WO disclosed
WO-2009129109-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-10-22 — — WO disclosed
US-20090163714-A1 P70 S6 KINASE INHIBITORS ELI LILLY AND COMPANY 2009-06-25 — — US disclosed
WO-2008140947-A1 P70 S6 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2008-11-20 — — WO disclosed
EP-1874765-A2 UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF Proskelia SAS (FR) 2008-01-09 — — EP disclosed
WO-2006117211-A2 UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF PROSKELIA SAS (FR) 2006-11-09 — — WO disclosed
EP-0735142-B1 Process for producing (R)-styrene oxides SUMIKA FINE CHEMICALS CO LTD (JP) 2001-10-24 — — EP disclosed
US-5717116-A TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) 1998-02-10 — — US disclosed
EP-0735142-A2 Process for producing (R)-styrene oxides SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) 1996-10-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182452-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER PDE3A, PDE3B, PDE5A PTPN1 1029/4885GSK3B 1199/4885TAS1R3 2815/4885
US-20230292759-A1 PHENYL COMPOUND AND PLANT DISEASE CONTROL METHOD H1-3, H1-0, H1-10 PTPN1 2422/4885GSK3B 2828/4885TAS1R3 2300/4885
US-11773070-B2 Dihydrooxadiazinones CCND2, DPYD, DHPS PTPN1 2719/4885GSK3B 2451/4885TAS1R3 4623/4885
US-12258323-B2 Dihydrooxadiazinones CCND2, CCNT2, CCND1 PTPN1 2650/4885GSK3B 2356/4885TAS1R3 4633/4885
US-20090163714-A1 P70 S6 KINASE INHIBITORS RPS6KA6, RPS6KA1, RPS6KA2 PTPN1 1121/4885GSK3B 546/4885TAS1R3 4642/4885
US-11897867-B2 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer PDE3B, PDE3A, PDE5A PTPN1 1605/4885GSK3B 515/4885TAS1R3 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.